39th week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150265659 | COMPOSITION FOR CONTROLLING FISH - The present invention relates to a composition for controlling fish. In particular, the composition may be an incitant, functioning as either a fish attractant or a fish repellent. The composition may be prepared by extracting bacteria from a source fish, culturing the bacteria in an appropriate media, and subsequently combining the cultured bacteria with a substrate to form the composition. | 2015-09-24 |
20150265660 | METHODS FOR MAKING AND USING ANTIMICROBIAL PEPTIDES - Provided herein are genetically modified microbes. In one embodiment, a genetically modified microbe includes an exogenous polynucleotide comprising a pheromone-responsive region. In one embodiment, the pheromone-responsive region is derived from a conjugative plasmid from a member of the genus | 2015-09-24 |
20150265661 | PREBIOTIC EFFECT OF SIALYLLACTOSE - Provided herein are prebiotic compositions comprising a combination of oligosaccharides such as sialyated oligosaccharides and fusocylated oligosaccharides, and uses thereof in stimulating the proliferation of beneficial intestinal micro biota, for example, of bifidobacteria, and/or in decreasing the abundance of enteric pathogens. The prebiotic compositions can further contain a probiotic, which can be a population of bifidobacteria, lactobacilli, | 2015-09-24 |
20150265662 | LAYERING AND MICROENCAPSULATION OF THERMAL SENSITIVE BIOLOGICALLY ACTIVE MATERIAL USING HEAT ABSORBING MATERIAL LAYERS HAVING INCREASING MELTING POINTS - A layered microencapsulation structure and a method of preparation of the layered structure are provided herein. The layered microcapsules comprises different coating layers having a specific arrangement order where each layer is composed of at least one phase change material which is able to absorb heat from surroundings and still to keep constant temperature or an insignificant increase in temperature via a fusion process occurring at a specific temperature (e.g. melting point) and a core substrate that has a heat-sensitive component which is entrapped therein. The layered microencapsulation structure is designed in such a way that the layers are arranged with increasing order of the melting point from inside to outside. The method of microencapsulation comprises the step of dry cold granulation of a sensitive active material using a melt material resulting in a core substrate and layering using heat absorbing materials having increasing melting points. The core substrate is coated by different layers of phase change material having different melting points resulting in a layered microcapsule structure. After layering process the layered microcapsule may be optionally coated by an outermost layer which is soluble in GI tract. | 2015-09-24 |
20150265663 | METHOD FOR SUPPRESSING ADIPOCYTE FORMATION - Provided are a naturally-derived agent for suppressing differentiation into adipocyte, readily available and ingestible in daily dietary life and having little side effects, a method for suppressing differentiation into adipocyte in a subject in need thereof, and the like. The present inventors have confirmed that a water extract of | 2015-09-24 |
20150265664 | TRADITIONAL CHINESE MEDICINE COMBINATION FOR REGULATING IMMUNE FUNCTION AND PREPARATION METHOD THEREFOR - The present invention relates to a traditional Chinese medicine composition for regulating immunity and preparation method thereof, characterized in that the composition comprises raw materials such as Radix Panacis Quinquefolii, | 2015-09-24 |
20150265665 | MULTI-VITAMIN KIDS GUMMIES HAVING BAOBAB AND METHOD OF MAKING THEREOF - The embodiments herein relate to a multi-vitamin kids' gummies composition and a method of making the same. The multi-vitamin kids' gummies comprises a fruit powder, a thickening agent, a vitamin mix and water. The fruit powder is baobab fruit powder. The thickening agent is gelatine. The method of making multi-vitamin kids' gummies comprises mixing a predetermined amount of water and a predetermined amount of a thickening agent to obtain a mixture. The mixture is boiled to get a gel-like consistency. The mixture is cooled to room temperature. A predetermined amount of a fruit powder is added to the mixture. The fruit powder is baobab fruit powder. The mixture is kept at room temperature for at least 15 minutes and the mixture is molded to form gummies or candies. | 2015-09-24 |
20150265666 | BOTANICAL ANTIMICROBIAL COMPOSITIONS - Disclosed herein are antimicrobial compositions comprising mixtures of botanical extracts, synthetic antimicrobial agents and essential oils which do not rely solely upon alcohol to produce their antimicrobial effects. | 2015-09-24 |
20150265667 | Composition Comprising Centipede Grass Extracts or Fractions Thereof as Active Ingredients - The present invention relates to a pharmaceutical composition for preventing or treating diabetes or dementia, comprising centipede grass ( | 2015-09-24 |
20150265668 | COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF - Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient. | 2015-09-24 |
20150265669 | METHODS AND COMPOSITIONS FOR INHIBITING CANCER CELL GROWTH - The present invention discloses compositions and methods for treating, as well as preventing and inhibiting blood and lung cancer by providing a safe, nutraceutical composition comprising a plant extract from the family Rubiaceae, Acanthaceae and Zingiberaceae. In more specific, the nutraceutical composition is capable of inducing apoptosis in leukemia and lung cancer cells, to reduce severity and incidence, without affecting growth of normal cells. | 2015-09-24 |
20150265670 | AGENT FOR PREVENTING OR IMPROVING DECLINE IN BRAIN FUNCTION - An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentration, decreased attention, decreased judgment ability, depression, and decreased exercise performance caused thereby. According to the present invention, an agent for protecting brain neuronal cells, comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients as well as an agent for preventing or improving decline in brain function, comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients is provided. | 2015-09-24 |
20150265671 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTIRYPSIN - The present invention provides compounds and methods for the treatment of an individual having or at risk of having a condition associated with alpha-1-antitrypsin by using a pharmacological chaperone. In particular, such methods are useful for the treatment and/or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. The present invention also provides an assay for determining whether a test compound modulates alpha-1-antitrypsin activity. | 2015-09-24 |
20150265672 | MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION - The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject. | 2015-09-24 |
20150265673 | SURGICAL APPLICATIONS FOR BMP BINDING PROTEIN - The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired. | 2015-09-24 |
20150265674 | POLY-GLUTAMIC ACID ANTI-ANTHRAX COMPOSITIONS AND METHODS FOR USING THE SAME - Methods and compositions for inhibiting entry of an anthrax toxin and/or an anthrax toxin protein into a cell are provided. Aspects of the subject methods include administering to a host an effective amount of poly-γ-Glutamic acid-Fe(III) chelate. Also provided are compositions suitable for use in the subject methods, as well as pharmaceutical preparations thereof. | 2015-09-24 |
20150265675 | Treatment of Brain Injury or Trauma with TSG-6 Protein - A method of treating brain injury or brain trauma in an animal by administering to an animal TSG-6 protein or a biologically active fragment, derivative, or analogue thereof. | 2015-09-24 |
20150265676 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) - The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD. | 2015-09-24 |
20150265677 | RECRUITMENT OF MENSENCHYMAL CELLS USING CONTROLLED RELEASE SYSTEMS - The present invention provides microparticles that deliver in vivo predictable release profiles of at least one chemokine to create a biomimetic chemokine concentration gradient that induces the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle. Local administration and/or intraarticular injection of the microparticles are useful in conditions such as osteoarthritis. Targeted systemic delivery of the alginate chemokine microparticles to distant anatomical sites subjected to autoimmune disease symptomology can be performed by encapsulation within liposomes having targeting ligands. Consequently, upon the creation of the appropriate chemokine gradient, multipotent stem cells will migrate to the distant anatomical site where the liposomes are attached. | 2015-09-24 |
20150265678 | METHODS OF TREATING COGNITIVE IMPAIRMENT - The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment. | 2015-09-24 |
20150265679 | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR - What is described is a method for treating an adverse side effect of MEK inhibitors by administering a pharmaceutical composition comprising IFNγ to a cancer patient being treated by a MEK-inhibitor. The applicants discovered that MEK inhibitors produce unwanted visual disturbances as an adverse side effect in a significant fraction of cancer patients being treated by the drug, and that the side effect causes retinal detachment due to fluid accumulation in the eye. The method treats the retinal detachment caused by the anticancer therapeutic by providing a means of decreasing the amount of fluid present in the retina and/or subretinal space of the eye by administering the pharmaceutical composition comprising IFNγ to the basolateral side of the retinal pigment epithelium, preferably by administering the pharmaceutical composition to the anterior surface of the eye in liquid droplets. | 2015-09-24 |
20150265680 | THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS - The present invention provides a therapeutic agent for amyotrophic lateral sclerosis comprising a growth hormone secretagogue receptor (GHS-R) agonist or a pharmaceutically acceptable salt thereof as an active ingredient. An object of the present invention is to provide a pharmaceutical product for amyotrophic lateral sclerosis for which no effective drug exists. The therapeutic agent for amyotrophic lateral sclerosis of the present invention comprises a GHS-R agonist typified by ghrelin as an active ingredient and is administered to a recipient individual having amyotrophic lateral sclerosis with non-serious dysphagia. The individual may also be unresponsive or insufficiently responsive to an existing therapeutic agent for ALS. | 2015-09-24 |
20150265681 | STABILIZATION OF FSH - The present invention pertains in general to the field of stabilization of FSH formulations, in particular liquid FSH formulations. The stabilization is achieved by the addition of salts comprising pharmaceutically acceptable alkali metal cations, in preferred embodiments by the addition of pharmaceutically acceptable salts, i.e. sodium salts or potassium salts. | 2015-09-24 |
20150265682 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING DIABETES - The present invention is directed to therapeutic methods and compositions for treating type 1 diabetes in a subject comprising administering an effective amount of borapetoside A or C, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, and insulin to said subject. | 2015-09-24 |
20150265683 | Stable aqueous composition comprising human insulin or an analogue or derivative thereof - A stable aqueous insulin preparation comprising human insulin, analogues or derivatives thereof, one or more solubility enhancing agents are selected from urea, amino acids and/or surfactants optionally one or more other pharmaceutically accept able excipient(s). | 2015-09-24 |
20150265684 | METHODS OF TREATING HEMOGLOBINOPATHIES - Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, β-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from a β-arrestin1/2 inhibitor and/or a GRK2 inhibitor to the subject. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells and adhesion to and activation of leukocytes are also provided. | 2015-09-24 |
20150265685 | APYRASE THERAPY FOR FIBROPROLIFERATIVE DISORDERS, PULMONARY HYPERTENSION, AND HEART FAILURE - This invention provides new methods of treating subjects with fibroproliferative disease such as pulmonary hypertension (e.g. pulmonary arterial hypertensions), posthrombotic syndrome associated with venous thrombosis, or ventricular heart failure associated with fibroproliferative disease. In each case, the treatment methods of the present invention comprise administering apyrase agents—for example, a soluble agent belonging to the class of CD39 apyrases, optionally CD39L apyrase family, or optionally CD39L3 apyrases. Also provided are methods of diagnosing pulmonary arterial hypertension comprising quantifying cytokines in biological fluids and examining the values for those elevated in comparison to normal control values. | 2015-09-24 |
20150265686 | TREATMENT OF GLUTEN INTOLERANCE AND RELATED CONDITIONS - Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. | 2015-09-24 |
20150265687 | COOPERIA VACCINE - The present invention relates to nucleotide sequences encoding | 2015-09-24 |
20150265688 | Stabilizing Formulations for Recombinant Viruses - This invention relates to preparations of viruses, e.g. for vaccine or other pharmaceutical or research use, to their stabilization, and to processes of producing such preparations, as well as to their use, e.g. as vaccines or as virus vectors. The formulations comprise a sugar, a preservative, a dispersing agent, a thermal stability agent, a buffer, and up to three distinct types of amino acids without impacting the structural appearance of the lyophilized product. | 2015-09-24 |
20150265689 | FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME - An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below:
| 2015-09-24 |
20150265690 | PLASMODIUM FALCIPARUM SPOROZOITE AND LIVER STAGE ANTIGENS - The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation. | 2015-09-24 |
20150265691 | Anthrose-based compositions and related methods - This invention provides a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against | 2015-09-24 |
20150265692 | IMMUNOGENIC COMPOSITION COMPRISING AN INACTIVATED RECOMBINANT NON-PATHOGENIC BACTERIUM - The present invention relates to immunogenic compositions, vaccines and antibodies for the treatment and/or prevention of infections and diseases caused by | 2015-09-24 |
20150265693 | THERAPEUTIC AGENT FOR CANCER - The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses. | 2015-09-24 |
20150265694 | VACCINES AND METHODS FOR CREATING A VACCINE FOR INDUCING IMMUNITY TO ALL DENGUE VIRUS SEROTYPES - Described here is a method to produce a chimeric protein having portions of yellow fever virus and dengue virus. A small portion of the yellow fever virus 17D vaccine strain envelope protein (or other related | 2015-09-24 |
20150265695 | VACCINE COMPOSITIONS FOR PREVENTION AGAINST DENGUE VIRUS INFECTION - The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease. | 2015-09-24 |
20150265696 | Compositions And Methods For Treating And Preventing Porcine Reproductive And Respiratory Syndrome - Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject. | 2015-09-24 |
20150265697 | HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR GENERATING VIRUS-LIKE PARTICLES - Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described. | 2015-09-24 |
20150265698 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 2015-09-24 |
20150265699 | Recombinant Novirhabdovirus Usable as an Antigen Vector - The invention relates to a recombinant | 2015-09-24 |
20150265700 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 2015-09-24 |
20150265701 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR - The present invention discloses immunomodulating compositions. More particularly, the present invention discloses compositions comprising an immune-modulating agent and a lectin-interactive agent, which are useful for stimulating and prolonging host immune cell responses. The compositions of the present invention are particularly useful in the treatment and/or prophylaxis of a range of conditions including pathogenic infections, autoimmune diseases, transplant rejection, graft versus host disease, allergies, inflammatory disease, as well as cancers and tumours. | 2015-09-24 |
20150265702 | PNEUMOCCAL POLYSACCHRIDE CONJUGATE VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 2015-09-24 |
20150265703 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus. | 2015-09-24 |
20150265704 | IGM THERAPY IN PREVENTION OF ONSET, PROGRESSION, AND RECURRENCE OF AUTOIMMUNE TYPE 1 DIABETES - The therapeutic potential of polyclonal serum naturally occurring IgM (nIgM) administration in preventing the onset and progression of autoimmune type 1 diabetes and in promoting graft survival following islet allotransplantation has been investigated. nIgM therapy prevents both, onset and progression of diabetes and promotes islet graft survival. | 2015-09-24 |
20150265705 | PD-1 ANTIBODIES IN COMBINATION WITH A CYTOKINE-SECRETING CELL AND METHODS OF USE THEREOF - The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer. | 2015-09-24 |
20150265706 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP) - The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein. | 2015-09-24 |
20150265707 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS - Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed. | 2015-09-24 |
20150265708 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure | 2015-09-24 |
20150265709 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS - Therapeutic peptide compositions comprise a therapeutic peptide, such as insulin, together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino)propionate. | 2015-09-24 |
20150265710 | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery - The present invention relates to fatty acid acylated amino acids (FA-Daa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-Daa's. | 2015-09-24 |
20150265711 | SWEET FLAVOR MODIFIER - The present invention includes compounds having structural formula (I), or pharmaceutically acceptable salts, solvate, and/or ester thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of enhancing the sweet taste of ingestible compositions. Furthermore, the present invention provides methods for preparing the compounds. | 2015-09-24 |
20150265712 | DRUG DELIVERY USING ELECTROCHEMICALLY-TRIGGERED BIODEGRADABLE ELECTROACTIVE MATERIALS - A biodegradable electroactive material can be doped with a drug and the drug can be delivered to a living subject by stimulating the material with an electrical potential. The material (in this case a polymer) has an electrochemically responsive oligoaniline block terminated with a carboxylic acid moiety and is linked to an alcohol-terminated diol by an ester bond. Advantageously, the diol is PEG-400, PEG-2000, PCL-530, or PCL-2000. | 2015-09-24 |
20150265713 | Phenylephrine Formulations With Improved Stability - A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity. | 2015-09-24 |
20150265714 | COMPOSITE FOR PREPARING A TRANSDERMAL DELIVERY DEVICE AND METHOD FOR SYNTHESIZING THE COMPOSITE THEREOF - A composite for preparing a transdermal delivery device and a method for synthesizing the composite thereof comprising at least one polymer and at least one macrocyclic molecule, wherein the at least one polymer and the at least one macrocyclic molecule are adapted to form a complex. | 2015-09-24 |
20150265715 | POSACONAZOLE INTRAVENOUS SOLUTION FORMULATIONS STABILIZED BY SUBSTITUTED BETA-CYCLODEXTRIN - The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties. | 2015-09-24 |
20150265716 | Nanoparticles For Targeted Delivery of Multiple Therapeutic Agents and Methods of Use - Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles. | 2015-09-24 |
20150265717 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY - Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation. | 2015-09-24 |
20150265718 | SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES - The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the | 2015-09-24 |
20150265719 | SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES - The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the | 2015-09-24 |
20150265721 | Compounds and Methods for Modulating an Immune Response - The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. | 2015-09-24 |
20150265722 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES - Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers. | 2015-09-24 |
20150265723 | METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 - Methods of treating patients having metastatic or unresectable locally advanced HER2 positive cancer, e.g., breast cancer, with the antibody-drug conjugate trastuzumab-MCC-DM1 are provided, wherein the patients have received extensive prior treatment, e.g., with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. | 2015-09-24 |
20150265724 | ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat tumors having neuroendocrine features are provided. | 2015-09-24 |
20150265725 | METHOD AND COMPOSITION FOR HYPERTHERMALLY TREATING CELLS - A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. | 2015-09-24 |
20150265726 | ORGANIC NANOQUENCHER BASED ON CONJUGATED POLYMER AND PREPARATION METHOD THEREOF - A pH responsive quencher based on a conjugated polymer and responding to an in vivo redox reaction and a preparation method thereof are provided. The pH responsive quencher can evaluate a metabolism environment according to a pH value in vivo with a characteristic that an absorption wavelength band sensitively changes depending on a pH condition. | 2015-09-24 |
20150265727 | PREPARATION OF IOFORMINOL, AN X-RAY CONTRAST AGENT - The present invention relates to a process for the preparation of Ioforminol, a contrast agent useful in X-ray imaging. More particularly, the invention relates to preparation of Ioforminol from a compound mixture comprising 1-formylamino-3,5-bis(2,3-bis(formyloxy)propan-1-ylcarbamoyl)-2,4,6-trioodobenzene by a process comprising in situ hydrolysis and a bis-alkylation. | 2015-09-24 |
20150265728 | MAGNETIC AND FLUORESCENT REVERSE NANOASSEMBLIES - The present invention relates to magnetic and fluorescent nanoassemblies having reverse architectures. Especially, the nanoassemblies of the invention comprise a fluorescent core and magnetic nanoparticles contacting the surface of the fluorescent core. The nanoassemblies of the invention may further be coated by a polymer, which may optionally be functionalized. The invention further relates to a process for manufacturing the nanoassemblies of the invention. The invention is also directed to the use of the nanoassemblies of the invention, especially for multimodal imaging, in vitro and/or in vivo diagnostics through multimodal imaging, and/or therapy. | 2015-09-24 |
20150265729 | ROD-SHAPED PLANT VIRUS NANOPARTICLES AS IMAGING AGENT PLATFORMS - A rod-shaped plant virus having an interior surface and an exterior surface, and at least one imaging agent that is linked to the interior and/or exterior surface is described. The rod-shaped viruses can be combined into larger spherical nanoparticles. A rod-shaped plant virus or spherical nanoparticles including an imaging agent can be used in a method of generating an image of a tissue region of a subject such as a tumor or atherosclerotic tissue by administering the virus particle to the subject and generating an image of the tissue region of the subject to which the virus particle has been distributed. | 2015-09-24 |
20150265730 | METHOD OF OVERCOMING THERAPEUTIC LIMITATIONS OF NONUNIFORM DISTRIBUTION OF RADIOPHARMACEUTICALS AND CHEMOTHERAPY DRUGS - Disclosed is a method for predicting the optimal amounts of radiopharmaceutical and/or chemotherapy agents to administer to a patient, by determining the level of saturation of the therapeutic agents in the patient's cells. The method comprises measuring cellular incorporation of the candidate therapeutic agents in a target cell population on a cell-by-cell basis. The method is able to identify an optimal cocktail of therapeutic agents for treatment of a disease. A method of high-throughput drug discovery incorporating this method, and a 2-stage targeting method of treating a disease using this method are also disclosed. | 2015-09-24 |
20150265731 | METHOD TO IMPROVE THE TUMOR DIAGNOSTIC EFFICIENCY OF MULTIVALENT LIGANDS BY REGULATING THE STOICHIOMETRIC RATIO BETWEEN INNER SURFACE FUNCTIONALITIES AND LIGAND MOIETIES FOR TUMOR TARGETING - Disclosed herein is a method of improving tumor diagnostic efficiency of multivalent ligands by regulating the stoichiometric ratio between inner surface functionalities and ligand moieties for tumor targeting, and the multivalent ligands for tumor diagnosis. | 2015-09-24 |
20150265732 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER - The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods. | 2015-09-24 |
20150265733 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES - To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an Integer from 1 to 3 and n is an integer from 1 to 6. | 2015-09-24 |
20150265734 | Light Irradiation Apparatus - In a light irradiation apparatus, an elongated body has flexibility that allows for elastic restoration. An LED chip is closely fixed to a tip portion of the elongated body and emits ultraviolet light. A cover unit covers the LED chip so as to protect the LED chip and allows the ultraviolet light emitted by the LED chip to pass through the cover unit. A conductive unit extends in a longitudinal direction of the elongated body and passes electric current for allowing the LED chip to emit light. An insulation unit covers the conductive unit so as to ensure electrical insulation of the conductive unit. | 2015-09-24 |
20150265735 | UV DISINFECTION SYSTEM FOR NEEDLELESS CONNECTOR - A device is presented for disinfecting needleless connectors. The device has a housing that contains a UV light source. The UV light source is operably connected to a power source. The housing has a receptacle configured to selectively receive a shield. The shield has an inner reflective chamber with an internal surface that reflects UV light. In use, the UV light source can illuminate a needleless connector inserted within the shield. | 2015-09-24 |
20150265736 | METHODS AND SOLUTIONS FOR KILLING OR DEACTIVATING SPORES - Exemplary methods and systems for killing or deactivating spores include applying a fluid to a surface containing a spore; and applying direct or indirect plasma to the surface for a period of time. In some embodiments, the fluid includes water. In some embodiments, the spore is | 2015-09-24 |
20150265737 | METHOD FOR TREATING USED ABSORBENT ARTICLE - Provided is a method for treating a used absorbent article, this method being hygienic and capable of recovering recyclable material with a high degree of safety. This method for treating a used absorbent article is characterized by including (a) an acidic electrolyzed water treatment step that treats the used absorbent article in a treatment tank that has acidic electrolyzed water serve as a treatment fluid. This method preferably further includes (b) an alkaline electrolyzed water treatment step that treats the used absorbent article in a treatment tank that has alkaline electrolyzed water as a treatment fluid. | 2015-09-24 |
20150265738 | SATURATION-ENHANCED, LOW-CONCENTRATION VAPORIZED HYDROGEN PEROXIDE DECONTAMINATION METHOD - A method for decontaminating an object disposed in a region. The method includes the steps of: heating the region to a target temperature; introducing steam into the region until a humidity level in the region reaches a target humidity level; introducing a vaporized sterilant into the region until a sterilant concentration in the region reaches a target sterilant concentration; and maintaining the target temperature, the target sterilant concentration and the target humidity level until a predetermine target dose is obtained. | 2015-09-24 |
20150265739 | Ink Jet Delivery System Comprising an Improved Fluid Mixture - Ink jet delivery systems for a fluid composition comprising from about 50% to about 100%, by weight of the composition, of an active mixture. The active mixture having a vapor pressure less than about 2.3 kPa at 20 C. The composition also comprising about 0% to 50%, by weight, of a carrier volatile composition having a vapor pressure above about 2.3 kPa at 20 C and an ink jet head for delivering the fluid composition into the air. | 2015-09-24 |
20150265740 | GAS PROCESSING APPARATUS - A gas processing apparatus of an embodiment includes: first and second dielectric substrates facing with each other; first and second discharge electrodes respectively disposed on a pair of facing principal surfaces of the dielectric substrates; first and second ground electrodes respectively disposed on a pair of principle surfaces at opposite sides of the principle surfaces of the dielectric substrates; a gas flow path to supply gas to be processed between the discharge electrodes; an AC power source to generate first and second plasma-induced flows by applying an AC voltage between the discharge electrodes and the ground electrodes; and a region disposed between the dielectric substrates at downstream of the plasma-induced flows from the discharge electrodes, and a gap between the dielectric substrates being 1.3 times or less of a sum of thicknesses of the plasma-induced flows. | 2015-09-24 |
20150265741 | WOUND MANAGEMENT SYSTEM AND METHODS OF USING - A wound management system can comprise a surgically acceptable adhesive disposed over a wound and a surgically acceptable film repositionably disposed over the surgically acceptable adhesive, and methods of managing a wound involving the same. | 2015-09-24 |
20150265742 | PRESSURE-SENSITIVE ADHESIVE TAPE OR SHEET FOR APPLICATION ON SKIN - A pressure-sensitive adhesive tape or sheet for application on skin includes a substrate and a pressure-sensitive adhesive layer laminated on at least one surface of the substrate. The pressure-sensitive adhesive layer contains: 100 parts by weight of an acrylic copolymer prepared by copolymerizing a monomer mixture comprising from 5 to 38% by weight of an alkyl (meth)acrylate monomer, from 61 to 90% by weight of an alkoxy group-containing ethylenic unsaturated monomer and from 1 to 10% by weight of a carboxyl group-containing ethylenic unsaturated monomer; and from 30 to 60 parts by weight of a carboxylic acid ester in a paste form or liquid form at room temperature. The acrylic copolymer has been subjected to a crosslinking treatment. | 2015-09-24 |
20150265743 | Sulfhydryl-Functionalized Polymeric Compositions For Medical Devices - The present disclosure provides sulfhydryl-modified polymer foams, which may be used for wound dressing materials. For example, the modified materials can include free sulfhydryl group, which can serve as a linker to attach biologically active molecules. For example, sulfhydryl groups can be used to conjugate biologically active polypeptides and/or metals to foam polymers. Methods for using sulfhydryl-modified polymers, such as for wound dressings, are also provided. | 2015-09-24 |
20150265744 | Multilayer preform obtained by electro-spinning, method for producing a preform as well as use thereof - The invention relates a multilayer preform obtained by electro-spinning, which preform is suitable as a scaffold for a prosthesis, which preform comprises layers of different diameter microfibers. The present invention also relates to a method of producing said preform. The present invention also relates to the use of the present preform as a substrate for growing human or animal tissue thereon. The present invention furthermore relates to a method for growing human or animal tissue on a substrate, wherein the present preform is used as the substrate. | 2015-09-24 |
20150265745 | Porous and Nonporous Materials for Tissue Grafting and Repair - Composite materials having improved mechanical properties and/or degradation profiles, devices and implants, kits including such implants, and methods of producing and using the same. | 2015-09-24 |
20150265746 | MICRO-FIBER WEBS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF PRODUCED BY CENTRIFUGAL SPINNING - Methods to produce micro-fiber webs containing fibers of 4-hydroxybutyrate or copolymers thereof with average diameters from 0.01 to 100 μm, have been developed. The micro-fiber webs are produced by centrifugal spinning. These methods allow the micro-fiber webs to be produced without substantial loss of the polymer weight average molecular weight. Webs containing micro-fibers of poly-4-hydroxybutyrate or copolymer thereof, are made by centrifugal spinning. The micro-fibers have average diameters ranging from 0.01 to 100 μm and contain crimped fibers with a higher elongation at break fibers when compared to fibers derived by melt-blown extrusion, dry spinning and electrospinning. The fibers of the micro-fiber webs have a high degree of orientation. These micro-fiber webs can be used for a variety of purposes including fabrication of medical devices. | 2015-09-24 |
20150265747 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion. | 2015-09-24 |
20150265748 | PARTICULATE TISSUE GRAFT WITH COMPONENTS OF DIFFERING DENSITY AND METHODS OF MAKING AND USING THE SAME - Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient. | 2015-09-24 |
20150265750 | FIBER WADDING FOR FILLING BONE DEFECTS - A method for producing a flocculent three dimensional fibrous bioactive material using an electrospinning process includes electrospinning a biodegradable fiber by applying an electrical charge to a nozzle of an electrospinning apparatus such that a spinning solution contained therein is made into an electrospun fiber, which is attracted toward a collector container that is electrically grounded and is filled with an ethanol liquid; receiving the electrospun fiber emitted from the nozzle on a surface of the ethanol liquid in the collector container; recovering and drying the electrospun fiber to obtain the flocculent three dimensional fibrous bioactive material having a bulk density of from about 0.01 g/cm | 2015-09-24 |
20150265751 | SYSTEM FOR PREVENTING BACTERIAL INFECTIONS IN NEEDLE TRAJECTORIES - System for preventing bacterial infections in needle trajectories. The system includes
| 2015-09-24 |
20150265752 | Topical agents for the treatment of sensory discomfort in the nasal cavity - The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds with a swab to the Kiesselbach's area of the human nose will relieve the discomforts of rhinitis and other nasal cavity discomforts. | 2015-09-24 |
20150265753 | BREAST PUMP SYSTEM - A breast pump system. The system includes a pump for generating suction; at least one breast shield; a first bottle operatively coupled to the breast shield for collecting milk; tubing connected between the pump and the breast shield for transmitting suction from the pump to the breast shield to draw milk into the breast shield; and a controller in communication with the pump. The controller is configured to control the pump to generate different suction levels in a cyclic manner at a frequency, control the pump to start and stop pumping, collect input from a user of an amount of milk collected, and store information for at least one pumping session. | 2015-09-24 |
20150265754 | DRESSING AND APPARATUS FOR CLEANSING THE WOUNDS - A dressing ( | 2015-09-24 |
20150265755 | BIOLOGICAL FLUID FILTERS WITH MOLDED FRAME AND METHODS FOR MAKING SUCH FILTERS - Flexible housing filters for filtration of fluids and methods of making such filters are disclosed. The filters include a molded frame with no peripheral seal that houses a filter medium. | 2015-09-24 |
20150265756 | BLOOD TREATMENT FILTER, BLOOD CIRCUIT, AND BLOOD TREATMENT METHOD - A blood treatment filter including: a filter container that introduces blood from an inlet into an internal space, and discharges treated blood from an outlet; a filter material that is housed in the filter container to partition the internal space into an inlet side space and an outlet side space, and filters the passing blood to remove a specific component; an inlet port that forms an inlet channel through which the blood flowing from the inlet to the internal space passes; an outlet port that forms an outlet channel through which the blood flowing from the internal space to the outlet passes, wherein the outlet channel has a tapered outlet passage with an inner diameter increasing from the internal space side toward the outlet side. | 2015-09-24 |
20150265757 | DEVICES, METHODS AND SYSTEMS FOR COUNTERPULSATION AND BLOOD FLOW CONDUIT CONNECTION - A blood flow conduit includes a first conduit portion defining a first portion of a lumen; and a second conduit portion defining a second portion of a lumen. At least one of the first or second conduit portions may include a tip portion and the other of the first or second conduit portions may include an enlarged area. | 2015-09-24 |
20150265758 | FLEXIBLE BIOLOGICAL FLUID FILTERS - Filter assemblies are processing biological fluid, such as blood or a blood component containing leukocytes. The filter assemblies include a flexible housing with first and second walls. A filtration medium and a support member are at least partially positioned between the walls of the housing, with a seal joining the walls of the housing, the filtration medium, and the support member. The filter assemblies may further include a pre-filter and/or a post-filter positioned between the walls of the housing. If provided, the pre- and post-filter may be positioned on opposite walls of the filtration medium, with the post-filter being a mesh positioned between the filtration medium and one of the walls of the housing or within an opening defined by the support member. A seal of the filter assembly may pass through the filtration medium, with the filtration medium being substantially omitted in a section of the seal. | 2015-09-24 |
20150265759 | METHOD FOR CONTROLLING A DISINFECTION STATUS OF A TEMPERATURE CONTROL DEVICE AND TEMPERATURE CONTROL DEVICE FOR HUMAN BODY TEMPERATURE CONTROL DURING EXTRACORPOREAL CIRCULATION - The present application relates to a method for controlling a disinfection status of a heater and/or cooler for human body temperature control during extracorporeal circulation. The temperature control is conducted by use of a heat exchanger and a temperature control liquid circulating through the heat exchanger and the heater and/or cooler. The inventive method comprises using a long term disinfectant in the temperature control liquid, measuring and preferably recording the concentration of the disinfectant in the temperature control liquid and deducing a disinfectant status of the temperature control liquid from the measured concentration of the disinfectant in the temperature control liquid. | 2015-09-24 |
20150265760 | CASSETTE SYSTEM INTEGRATED APPARATUS - A cassette integrated system. The cassette integrated system includes a mixing cassette, a balancing cassette, a middle cassette fluidly connected to the mixing cassette and the balancing cassette and at least one pod. The mixing cassette is fluidly connected to the middle cassette by at least one fluid line and the middle cassette is fluidly connected to the balancing cassette by at least one fluid line. The at least one pod is connected to at least two of the cassettes wherein the pod is located in an area between the cassettes. | 2015-09-24 |